Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

NCT05661240 | Unknown Phase 2

• 1 other identifier: P100-NSCLC2
• Study Type: interventional
• Target: 348
• Locations: 1 country
• Sites: 1

Brief Summary

The tumor treating fields（EFE-P100）generates alternating electric field during operation, and the tumor treating fields（EFE-P100）has a specific frequency and a specific field intensity. The tumor treating fields（EFE-P100）patch acts on the corresponding part of the patient and prevents the mitosis of tumor cells. This study was divided into two phases including phase II and phase III clinical trials. The main purpose of phase II clinical trial is to evaluate the safety of tumor treating fields（EFE-P100） combined with docetaxel injection in the second-line treatment of stage IV non-small Cell Lung Cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment. The main purpose of phase III clinical trial is to compare the efficacy of tumor treating fields（EFE-P100） combined with docetaxel injection and docetaxel injection alone in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment.

Conditions

Non-small Cell Lung Cancer (NSCLC)

Outcome Measures

Primary Outcomes (1)

• Progression-free survival (PFS)

  Progression-free survival is defined as the time from the start of treatment with Tumor Treating Fields（EFE-P100） and Docetaxel until the first documentation of disease progression or death due to any cause, whichever occurs first

  Up to 2 years

Secondary Outcomes (5)

• Number of participants with adverse events (AEs)

  The whole study period，an average of 2 year

• Objective response rate (ORR)

  Up to 2 years

• Overall survival (OS)

  up to 12 months after the last study treatment

• 12-month OS rate

  12 months

• Progression Free Survival rate at 6 months

  6 months

Study Arms (2)

Tumor treating fields combined with docetaxel injection

EXPERIMENTAL

Medical device：Tumor treating fields（EFE-P100） Tumor treating fields（EFE-P100）will be used each day. Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.

Device: Tumor treating fields（EFE-P100）; Drug: Docetaxel injection

docetaxel injection

ACTIVE COMPARATOR

Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.

Drug: Docetaxel injection

Interventions

Tumor treating fields（EFE-P100） DEVICE

Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.

Tumor treating fields combined with docetaxel injection

Docetaxel injection DRUG

Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.

Tumor treating fields combined with docetaxel injection; docetaxel injection

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 and ≤80, both sexes;
• Expected survival time ≥3 months;
• Non-small cell lung cancer was confirmed histologically or cytologically and classified as stage IV NSCLC according to the American Joint Committee on Cancer（AJCC）of eighth edition.
• Imaging progression (according to RECIST V1.1 criteria) or clinical progression during previous anti-PD - (L) 1 antibody and platinum-containing therapy or after treatment; - Neoadjuvant or adjuvant therapy, such as disease recurrence or progression ≤6 months after the end of treatment, counted as first-line treatment; - Prior treatment with at least 2 cycles of anti-PD - (L) 1 antibody, allowed as a single agent or in combination with platinum-based chemotherapy.
• At least one measurable or evaluable lesion according to RECIST version 1.1;
• ECOG 0-1;
• Concomitant Adverse Event（AE） after previous treatment should return to normal level or Common Terminology Criteria for Adverse Events（CTCAE） grade 1;
• Voluntarily sign informed consent.

You may not qualify if:

• Epidermal growth factor receptor（EGFR）-activating mutations or Anaplastic Lymphoma Kinase（ALK） fusion gene was positive; However, if squamous non-small cell lung cancer has not been tested before, it can no longer be tested and allowed to be enrolled.
• Untreated brain metastases, or with meningeal metastases, spinal cord compression, etc. Patients who had received previous treatment for brain metastases and were asymptomatic if they had been stable for at least 4 weeks on imaging before randomization and had stopped systemic hormone therapy (dose \>10mg/ day prednisone or other equivalent hormone) for more than 2 weeks were eligible.
• Severe bone injury due to bone metastases, including severe bone pain that is poorly controlled, pathologic fractures of major sites that have occurred within the last 6 months or are expected to occur in the near future.
• Previous docetaxel therapy or docetaxel-containing combination therapy;
• There are contraindications to docetaxel treatment or a known severe allergy to docetaxel;
• A history of diagnosis of a tumor other than small-cell lung cancer and antitumor therapy within 5 years prior to enrollment, excluding treated stage I prostate cancer, cervical or uterine cancer in situ, breast cancer in situ, and non-melanoma skin cancer;
• Abnormal bone marrow, heart, liver and kidney function: A. Neutrophil count \<1.5×109/L, platelet count \<100×109/L, hemoglobin \<90 g/L; TBiL\> upper normal value (ULN); AST and/or ALT\>2.5×ULN; ALP\>2.5×ULN (\>5×ULN if bone metastases are present); C. Serum creatinine \>1.5×ULN; Creatinine clearance rate \<50 mL/min;
• A history of severe cardiovascular disease, including second/third degree heart block; Severe ischemic heart disease; Poor control of hypertension; New York Heart Association (NYHA) class II or worse congestive heart failure (mild physical activity limitation; Comfortable at rest, but normal activities can cause fatigue, palpitations, or difficulty breathing);
• Patients who required systemic corticosteroid (other corticosteroid at a dose of more than 10mg prednisone per day or an equivalent physiologic dose) or other immunosuppressive agents within 14 days prior to enrollment or during the study period were eligible for enrollment if: A. The use of topical or inhaled glucocorticoids is permitted; B. Allow short-term (≤7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;
• If she had severe infection before the first treatment, the investigator judged that she was not suitable to participate in this study.
• A history of human immunodeficiency virus (HIV) infection (known HIV1/2 antibody positive);
• The presence of active hepatitis B, active hepatitis C, or other active infections that the investigator determines may affect the patient's treatment;
• There is a definite history of neurological or psychiatric disorders (e.g., epilepsy, dementia) or drug use or alcohol abuse within the last year that may affect trial compliance;
• Symptomatic ascites, pleural effusion, pericardial effusion, etc., except those who are stable after clinical treatment (including therapeutic puncture);
• Infection, ulceration and unhealed wound on the skin where the electrode is applied;

Sponsors & Collaborators

• Jiangsu Healthy Life Innovation Medical Technology Co., Ltd: lead

Study Sites (1)

Shanghai Pulmonary Hospital

Shanghai, China

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Docetaxel

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Zhou

  MD

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhou

CONTACT

02165115006; caicunzhou@yahoo.com.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2022
• First Posted: December 22, 2022
• Study Start: December 20, 2022
• Primary Completion: May 25, 2024
• Study Completion: July 31, 2025
• Last Updated: December 22, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)